A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China
Article in Targeted Oncology (January 2022)
The most recent citing publications are shown below. View all 5 publications that cite this research output on Dimensions.
Article in Targeted Oncology (January 2022)
Article in Journal of Oncology (December 2021)
Article in Journal of Thoracic Oncology (January 2020)